Workflow
CISEN(603367)
icon
Search documents
辰欣药业(603367.SH)股东韩延振拟减持不超3%股份
智通财经网· 2025-08-05 09:53
Core Viewpoint - Chenxin Pharmaceutical (603367.SH) announced a plan for share reduction by its shareholder Han Yanzhen, which will take place within three months after a 15 trading day period following the announcement [1] Summary by Category Share Reduction Plan - Han Yanzhen intends to reduce holdings through centralized bidding, with a maximum of 4.5275 million shares, accounting for no more than 1% of the company's total share capital [1] - Additionally, Han Yanzhen plans to reduce holdings via block trading, with a maximum of 9.0551 million shares, representing no more than 2% of the company's total share capital [1] - The total reduction will not exceed 13.5826 million shares, which is up to 3% of the company's total share capital [1]
辰欣药业股东韩延振拟减持不超3%股份
Zhi Tong Cai Jing· 2025-08-05 09:51
辰欣药业(603367)(603367.SH)发布公告,自公告披露之日起满15个交易日后的3个月内,根据市场情 况,做出适当减持安排。韩延振拟通过集中竞价交易方式减持数量不超过452.75万股,不超过公司总股 本的1%;拟通过大宗交易方式减持数量不超过905.51万股,不超过公司总股本的2%,合计减持数量不超 过1358.26万股,不超过公司总股本的3%。 ...
辰欣药业(603367) - 辰欣药业股份有限公司关于持股5%以上股东减持股份计划公告
2025-08-05 09:47
证券代码:603367 证券简称:辰欣药业 公告编号:2025-037 辰欣药业股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 持股 5%以上大股东持股的基本情况 本次减持计划实施前,辰欣药业股份有限公司(以下简称"公司"或"辰欣 药业")持股 5%以上股东韩延振持有辰欣药业无限售流通股份 31,977,829 股, 占辰欣药业总股本的 7.06%。 减持计划的主要内容 自本公告披露之日起满 15 个交易日后的 3 个月内,根据市场情况,做出适 当减持安排。韩延振拟通过集中竞价交易方式减持数量不超过 4,527,541 股,不 超过公司总股本的 1%;拟通过大宗交易方式减持数量不超过 9,055,082 股,不 超过公司总股本的 2%,合计减持数量不超过 13,582,623 股,不超过公司总股本 的 3%。在任意连续 90 日内,集中竞价减持股份的总数不超过公司股份总数的 1%, 大宗交易减持股份的总数不超过公司股份总数 2%。在上述减持计划实施 ...
辰欣药业:股东韩延振计划减持不超过约1358万股
Mei Ri Jing Ji Xin Wen· 2025-08-05 09:45
Group 1 - The core business of Chenxin Pharmaceutical is primarily in the pharmaceutical manufacturing sector, accounting for 99.75% of its total revenue for the year 2024 [1] - Other business activities contribute a minimal 0.25% to the overall revenue of Chenxin Pharmaceutical [1] Group 2 - As of August 5, Chenxin Pharmaceutical announced that major shareholder Han Yanzhen holds approximately 31.98 million shares, representing 7.06% of the total share capital [3] - Han Yanzhen plans to reduce his holdings by up to 4.53 million shares through centralized bidding, not exceeding 1% of the total share capital, and by up to 9.06 million shares through block trading, not exceeding 2% of the total share capital, totaling a maximum reduction of approximately 13.58 million shares or 3% of the total share capital [3] - The reduction plan allows for adjustments in case of corporate actions such as dividend distributions or stock splits during the implementation period [3]
辰欣药业:股东拟减持公司不超3%股份
人民财讯8月5日电,辰欣药业(603367)8月5日晚间公告,持股7.06%的股东韩延振拟通过集中竞价交 易和大宗交易方式合计减持公司股份不超过1358.26万股,不超过公司总股本的3%。 ...
辰欣药业(603367.SH):韩延振拟减持不超过3%股份
Ge Long Hui A P P· 2025-08-05 09:35
格隆汇8月5日丨辰欣药业(603367.SH)公布,自本公告披露之日起满15个交易日后的3个月内,根据市场 情况,做出适当减持安排。韩延振拟通过集中竞价交易方式减持数量不超过4,527,541股,不超过公司总 股本的1%;拟通过大宗交易方式减持数量不超过9,055,082股,不超过公司总股本的2%,合计减持数量 不超过13,582,623股,不超过公司总股本的3%。 ...
创新药概念冲高回落
Di Yi Cai Jing· 2025-08-05 03:24
Group 1 - The stock of Aonlikang is approaching a limit down, indicating significant selling pressure [1] - Several pharmaceutical companies, including Nanjing New Pharmaceutical, Huason Pharmaceutical, Yuekang Pharmaceutical, Chenxin Pharmaceutical, Guizhou Bailing, and Shutaishen, have all experienced declines exceeding 6% [1]
化学制药板块8月4日涨0.48%,海辰药业领涨,主力资金净流入9700.43万元
Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]
辰欣药业(603367)8月4日主力资金净流入7313.84万元
Sou Hu Cai Jing· 2025-08-04 07:45
Group 1 - The core viewpoint of the news is that Chenxin Pharmaceutical (603367) has experienced a stock price increase of 6.59% as of August 4, 2025, closing at 32.18 yuan, with a trading volume of 490,700 hands and a transaction amount of 1.511 billion yuan [1] - The company reported a total operating revenue of 920 million yuan for Q1 2025, a year-on-year decrease of 19.91%, and a net profit attributable to shareholders of 144 million yuan, down 11.86% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 3.540 and a quick ratio of 2.983, while the debt-to-asset ratio stands at 19.23% [1] Group 2 - Chenxin Pharmaceutical has made investments in 18 companies and has participated in 5,000 bidding projects, indicating active engagement in the market [2] - The company holds 230 trademark registrations and 290 patents, showcasing its commitment to intellectual property [2] - Additionally, the company possesses 610 administrative licenses, reflecting its regulatory compliance and operational capabilities [2]
辰欣药业上涨7.49%,报32.45元/股
Jin Rong Jie· 2025-08-04 05:53
8月4日,辰欣药业盘中上涨7.49%,截至13:38,报32.45元/股,成交11.7亿元,换手率8.5%,总市值 146.92亿元。 2025年1月-3月,辰欣药业实现营业收入9.2亿元,同比减少19.91%;归属净利润1.44亿元,同比减少 11.86%。 截至3月31日,辰欣药业股东户数2.14万,人均流通股2.12万股。 资料显示,辰欣药业股份有限公司位于济宁高新区同济科技工业园,公司是一家集研发、生产、销售于 一体的综合性制药企业,主要业务包括自主研发、生产能够填补国内空白的药品。公司每年将销售收入 的6%用于科技研发投入,已成功研制出阿德福韦酯等药品,并与多家科研院所建立了长期合作关系。 ...